Optimizing AAV Safety Summit

Temi della conferenza
Hundreds of clinical trials using AAV are underway, with several hundred more in preclinical development. Given the sheer volume of studies in the pipeline, the need to administer high doses, the clinical holds placed on gene therapy trials, and regulatory bodies being increasingly stringent on the safety standards they require; it has never been more important to create and implement an AAV safety strategy that's fit for purpose!

Professional congress organizer (PCO)
Hanson Wade

Annotazioni
Brochure: https://go.evvnt.com/1166061-3?pid=4832

Speakers: Anna Majowicz, Preclinical Immunology Lead, Spark Tx, Boris Gorovits, Vice President In Vitro Pharmacology and Bioanalysis, Sana Biotechnology, and more

https://go.evvnt.com/1166061-2?pid=4832

Ms. Emily Birt